Literature DB >> 10877923

Implantation of bioactive growth factor-secreting rods enhances fetal dopaminergic graft survival, outgrowth density, and functional recovery in a rat model of Parkinson's disease.

N Törnqvist1, L Björklund, P Almqvist, L Wahlberg, I Strömberg.   

Abstract

One of the drawbacks with fetal ventral mesencephalic (VM) grafts in Parkinson's disease is the limited outgrowth into the host striatum. In order to enhance graft outgrowth, epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) were administered by implantation of bioactive rods to the lateral part of the striatum to support grafted fetal VM implanted to the medial portion of the striatum. The polymer-based bioactive rods allow for a local secretion of neurotrophic factors over a time period of approximately 2 weeks. Moreover, glial cell line-derived neurotrophic factor (GDNF) and transforming growth factor-beta1 (TGFbeta1) were administered using the same technique. Concomitant administration of GDNF and TGFbeta1 was achieved by insertion of one GDNF and one TGFbeta1 rod. This was performed to investigate possible additive effects between GDNF and TGFbeta1. Rotational behavior, outgrowth from and nerve fiber density within the VM graft, and the number of TH-positive cells were studied. Functional compensation by reduction of rotational behavior was significantly enhanced in animals carrying bFGF and GDNF rods in comparison with animals carrying only VM graft. EGF and bFGF significantly increased the innervation density. Moreover, the nerve fiber density within the grafts was significantly enhanced by bFGF. Cell counts showed that a significantly higher number of TH-positive neurons was found in grafts treated with bFGF than that found in GDNF-treated grafts. An additive effect of TGFbeta1 and GDNF was not detectable. These results suggest that bioactive rods is a useful tool to deliver neurotrophic factors into the brain, and since bFGF was a potent factor concerning both functional, immunohistochemical and cell survival results, it might be of interest to use bFGF-secreting rods for enhancing the overall outcome of VM grafts into patients suffering from Parkinson's disease. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10877923     DOI: 10.1006/exnr.2000.7411

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  Preferential cell response to anisotropic electro-spun fibrous scaffolds under tension-free conditions.

Authors:  A English; A Azeem; D A Gaspar; K Keane; P Kumar; M Keeney; N Rooney; A Pandit; D I Zeugolis
Journal:  J Mater Sci Mater Med       Date:  2011-11-22       Impact factor: 3.896

2.  Effects of glial cell line-derived neurotrophic factor deletion on ventral mesencephalic organotypic tissue cultures.

Authors:  Sara af Bjerkén; Heather A Boger; Matthew Nelson; Barry J Hoffer; Ann-Charlotte Granholm; Ingrid Strömberg
Journal:  Brain Res       Date:  2006-12-19       Impact factor: 3.252

3.  The behavioral and biochemical effects of BDNF containing polymers implanted in the hippocampus of rats.

Authors:  Rachael W Sirianni; Peter Olausson; Amy S Chiu; Jane R Taylor; W Mark Saltzman
Journal:  Brain Res       Date:  2010-01-21       Impact factor: 3.252

4.  Aligned Protein-Polymer Composite Fibers Enhance Nerve Regeneration: A Potential Tissue-Engineering Platform.

Authors:  Sing Yian Chew; Ruifa Mi; Ahmet Hoke; Kam W Leong
Journal:  Adv Funct Mater       Date:  2007       Impact factor: 18.808

5.  Dynamic expression of bFGF and TGFbeta2 in glomus cell grafts of carotid body in rat model of Parkinson disease.

Authors:  Xuebing Cao; Shenggang Sun; Hongtao Liu; E'tang Tong; Huisheng Xia
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

6.  PTEN deletion enhances survival, neurite outgrowth and function of dopamine neuron grafts to MitoPark mice.

Authors:  YaJun Zhang; Ann-Charlotte Granholm; Kyounghee Huh; Lufei Shan; Oscar Diaz-Ruiz; Nasir Malik; Lars Olson; Barry J Hoffer; Carl R Lupica; Alexander F Hoffman; Cristina M Bäckman
Journal:  Brain       Date:  2012-09       Impact factor: 13.501

Review 7.  GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease.

Authors:  Xavier d'Anglemont de Tassigny; Alberto Pascual; José López-Barneo
Journal:  Front Neuroanat       Date:  2015-02-13       Impact factor: 3.856

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.